Cirio has advised Lauxera Capital Partners on a strategical investment in BioLamina

Cirio acted as legal advisor to Lauxera Capital Partners on €17 million investment in the Swedish cell culture company BioLamina AB (BioLamina).

Lauxera Capital Partners is an independent, international assets management company, focusing on growth companies in healthcare. Lauxera’s investment is made through the Lauxera Growth I fund, making only its second investment in the Nordics and its first investment in Sweden. BioLamina is a biotechnology company built on a scientific foundation with a legacy in matrix biology and cell culture-based research.

BioLamina will use the investment to expand the development and commercialization of laminins recombinant matrix proteins supporting biopharma companies as well as researchers in the maintenance, expansion, and differentiation of therapeutic stem cells and primary cells.

Bure Equity AB is a long-standing shareholder of BioLamina and the majority owner. Other investors and shareholders are Northislet AB, a Swedish investment company in emerging medical technologies as well as the BioLamina’s founders and executives.

Cirio’s team consisted of partners Anders Moberg (M&A) and Hanna Tilus (IP & Life Sciences), assisted by specialist counsel, Lisa Ericsson (employment law) and managing associate, Nicole Jerad (M&A).